• 1
    Etter J. F., Burri M., Stapleton J. The impact of pharmaceutical company funding on results of randomized trials of nicotine replacement therapy for smoking cessation: a meta-analysis. Addiction 2007; 102: 81522.
  • 2
    Fava M., Evins A. E., Dorer D. J., Schoenfeld D. A. The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom 2003; 72: 11527.
  • 3
    Stead L. F., Perera R., Bullen C., Mant D., Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2008; CD000146.
  • 4
    Stein D. J., Baldwin D. S., Dolberg O. T., Despiegel N., Bandelow B. Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram. J Clin Psychiatry 2006; 67: 17416.
  • 5
    Walsh B. T., Seidman S. N., Sysko R., Gould M. Placebo response in studies of major depression: variable, substantial, and growing. JAMA 2002; 287: 18407.